Literature DB >> 16988444

Vaccination with messenger RNA.

Steve Pascolo1.   

Abstract

As an alternative to DNA-based vaccines, messenger RNA (mRNA)-based vaccines present additional safety features: no persistence, no integration in the genome, no induction of autoantibodies. Moreover, mRNA which are generated by in vitro transcription, are easy to produce in large amounts and very high purity. This feature facilitates the good manufacturing practices process and guaranties batch-to-batch reproducibility. Vaccination can be achieved by several delivery methods including direct injection of naked mRNA, injection of mRNA encapsulated in liposomes Gene Gun delivery of mRNA loaded on gold beads or in vitro transfection of the mRNA in cells followed by re-injection of the cells into the patients. Two of these technologies are being evaluated in human clinical trials: (1) in vitro mRNA-transfection of dendritic cells to be adoptively transferred and (2) direct injection of globin-stabilized mRNA. This chapter describes the production of mRNA and the preparation of the two types of mRNA-based vaccines tested in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988444     DOI: 10.1385/1-59745-168-1:23

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  14 in total

1.  [Renal cell carcinoma associated proteins. Isolation, cloning and immunogenicity evaluation].

Authors:  A Haferkamp; M Hohenfellner; R Hautmann; M Zöller
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 2.  Developing mRNA-vaccine technologies.

Authors:  Thomas Schlake; Andreas Thess; Mariola Fotin-Mleczek; Karl-Josef Kallen
Journal:  RNA Biol       Date:  2012-10-12       Impact factor: 4.652

Review 3.  A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Authors:  Karl-Josef Kallen; Andreas Theß
Journal:  Ther Adv Vaccines       Date:  2014-01

4.  Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.

Authors:  Benjamin Petsch; Margit Schnee; Annette B Vogel; Elke Lange; Bernd Hoffmann; Daniel Voss; Thomas Schlake; Andreas Thess; Karl-Josef Kallen; Lothar Stitz; Thomas Kramps
Journal:  Nat Biotechnol       Date:  2012-11-25       Impact factor: 54.908

5.  Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 T cells against a lethal viral infection.

Authors:  Cory J Knudson; Pedro Alves-Peixoto; Hiromi Muramatsu; Colby Stotesbury; Lingjuan Tang; Paulo J C Lin; Ying K Tam; Drew Weissman; Norbert Pardi; Luis J Sigal
Journal:  Mol Ther       Date:  2021-05-14       Impact factor: 12.910

Review 6.  mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.

Authors:  Sandra Van Lint; Carlo Heirman; Kris Thielemans; Karine Breckpot
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

Review 7.  The notorious R.N.A. in the spotlight - drug or target for the treatment of disease.

Authors:  Philipp Reautschnig; Paul Vogel; Thorsten Stafforst
Journal:  RNA Biol       Date:  2016-07-14       Impact factor: 4.652

Review 8.  Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients.

Authors:  Emanuela Romano; Steve Pascolo; Patrick Ott
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

Review 9.  A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.

Authors:  Karl-Josef Kallen; Regina Heidenreich; Margit Schnee; Benjamin Petsch; Thomas Schlake; Andreas Thess; Patrick Baumhof; Birgit Scheel; Sven D Koch; Mariola Fotin-Mleczek
Journal:  Hum Vaccin Immunother       Date:  2013-06-04       Impact factor: 3.452

10.  An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs.

Authors:  Margit Schnee; Annette B Vogel; Daniel Voss; Benjamin Petsch; Patrick Baumhof; Thomas Kramps; Lothar Stitz
Journal:  PLoS Negl Trop Dis       Date:  2016-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.